Open AccessFixed‐Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes
Author(s) -
Ruilope Luis M.
Publication year - 2016
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12673
Subject(s) - medicine , amlodipine , olmesartan , perindopril , blood pressure , cardiology , clinical endpoint , tolerability , diabetes mellitus , fixed dose combination , randomized controlled trial , adverse effect , endocrinology
This post hoc analysis from the Sevikar Compared to the Combination of Perindopril Plus Amlodipine on Central Arterial Blood Pressure in Patients With Moderate‐to‐Severe Hypertension (SEVITENSION) study assessed the efficacy and tolerability of olmesartan ( OLM ) and amlodipine ( AML ) in reducing central systolic blood pressure ( CSBP ) compared with perindopril ( PER ) plus AML in hypertensive patients with type 2 diabetes. Patients were randomized to OLM / AML 40/10 mg or PER / AML 8/10 mg for 24 weeks. The primary efficacy endpoint was the absolute change in CSBP from baseline to week 24, which was greater with OLM / AML (−13.72±1.14 mm Hg) compared with PER / AML (−10.21±1.11 mm Hg). The between‐group difference was −3.51±1.60 mm Hg (95% confidence interval, −6.66 to −0.36 mm Hg) and was within the noninferiority margin (2 mm Hg) as well as the superiority margin (0 mm Hg). In addition, OLM / AML was associated with a higher proportion of patients achieving blood pressure normalization. In hypertensive patients with diabetes, the fixed‐dose combination of OLM / AML was superior to PER / AML in reducing CSBP , as well as other secondary endpoints.